{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:16:43Z","timestamp":1779293803420,"version":"3.51.4"},"reference-count":56,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,3,27]],"date-time":"2007-03-27T00:00:00Z","timestamp":1174953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gout is a common chronic arthritis that can lead to significant disability. Gout is one of the few rheumatological conditions that can be diagnosed with certainty, has a known cause and can be cured with appropriate therapy. Hypouricaemic agents reduce uric acid concentrations through inhibiting uric acid production (allopurinol) or enhancing uric acid excretion (probenecid, benzbromarone). Allopurinol is the most commonly used hypouricaemic agent but at recommended doses often fails to reduce adequately uric acid concentrations and prevent acute attacks of gout. The use of probenecid is limited by lack of efficacy in renal impairment. In the last few years, new agents in the management of hyperuricaemia and gout have become available. Febuxostat, a new xanthine oxidase inhibitor, is an effective hypouricaemic agent although further data are required for patients with renal impairment and other significant medical conditions. Rasburicase, a recombinant uricase (which catalyses the conversion of uric acid to the more readily excreted allantoin) is available for prevention of tumour lysis syndrome. However, its repeated use, as would be required in chronic gout, is limited by antigenicity. A less antigenic PEGylated uricase can rapidly reduce serum uric acid concentrations and promote resorption of tophi. However, further information with regard to the long\u2010term risks and benefits of these agents is required. These agents may ultimately be used in the short term to rapidly deplete urate stores (induction therapy) followed by long\u2010term therapy with an alternative hypouricaemic agent to prevent subsequent accumulation of uric acid (maintenance therapy).<\/jats:p>","DOI":"10.1111\/j.1445-5994.2007.01315.x","type":"journal-article","created":{"date-parts":[[2007,3,27]],"date-time":"2007-03-27T11:23:26Z","timestamp":1174994606000},"page":"258-266","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Emerging therapies in the long\u2010term management of hyperuricaemia and gout"],"prefix":"10.1111","volume":"37","author":[{"given":"L. K.","family":"Stamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. T","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,27]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80158-3"},{"key":"e_1_2_9_3_2","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li\u2010Yu J","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20102"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90743-5"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.03.043"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(04)00934-5"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000045939"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.10.006"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198611050-00001"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000162060.25895.a5"},{"key":"e_1_2_9_13_2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.1974.00320210163026","article-title":"Severe allopurinol hypersensitivity","volume":"134","author":"Young J","year":"1974","journal-title":"Arch Intern Med"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409500102"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.10.981"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2000.tb00857.x"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006058000800407"},{"key":"e_1_2_9_18_2","first-page":"2873","article-title":"Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis","volume":"27","author":"Harris M","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C"},{"key":"e_1_2_9_20_2","first-page":"437","article-title":"The pharmacology of hypouricaemic effect of benzbromarone","volume":"2","author":"Sinclair D","year":"1974","journal-title":"J Rheumatol"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.9.545"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197714050-00002"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/9.5.548"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10511"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0676.1995.tb00102.x"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2002.02692.x"},{"key":"e_1_2_9_27_2","first-page":"701","article-title":"Ten years experience with benzbromarone in the management of gout and hyperuricaemia","volume":"59","author":"Masbernard A","year":"1981","journal-title":"S Afr Med J"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.10.031"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20935"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200501000-00005"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000129082.42094.fc"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.11.6858"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000028589.66335.AA"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90039-3"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400850"},{"key":"e_1_2_9_37_2","first-page":"1942","article-title":"Uricase formulated with polyethylene glycol (Uricase\u2010PEG20): biochemical rationale and preclinical studies","volume":"29","author":"Bomalaski J","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_9_38_2","first-page":"S337","article-title":"A phase I study of pegylated uricase (Puricase) in subjects with gout","volume":"50","author":"Sundy J","year":"2004","journal-title":"Arthritis Rheum"},{"key":"e_1_2_9_39_2","article-title":"Resolution of tophi with intravenous PEG\u2010uricase in refractory gout","volume":"52","author":"Baraf H","year":"2005","journal-title":"Arthritis Rheum"},{"key":"e_1_2_9_40_2","doi-asserted-by":"crossref","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricaemia in subjects with refractory gout, and induction of antibody against poly(ethylene)glycol (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson N","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"e_1_2_9_41_2","first-page":"S679","article-title":"A phase 2 study of multiple doses of intravenous polyethylene glycol (PEG)\u2010uricase in patients with hyperuricaemia and refractory gout","volume":"52","author":"Sundy J","year":"2005","journal-title":"Arthritis Rheum"},{"key":"e_1_2_9_42_2","first-page":"4846","article-title":"Transformation of epithelial cells by stably transfected H2O2\u2010generating peroxisomal urate oxidase","volume":"56","author":"Chu R","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16000-5"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035700"},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20761"},{"key":"e_1_2_9_46_2","first-page":"1350","article-title":"Gout, diet and the insulin resistance syndrome","volume":"29","author":"Fam A","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_9_47_2","first-page":"773","article-title":"Gout: excess calories, purines, and alcohol intake and beyond; response to a urate\u2010lowering diet","volume":"32","author":"Fam A","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.7.539"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.22.3.339"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.26.1.112"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90106-7"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.04.005"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(02)00142-4"},{"key":"e_1_2_9_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1980.tb01670.x"},{"key":"e_1_2_9_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg103"},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.6.572"},{"key":"e_1_2_9_57_2","first-page":"39","article-title":"Deterioration in renal function associated with fibrate therapy","volume":"55","author":"Lipscombe J","year":"2001","journal-title":"Clin Nephrol"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2007.01315.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2007.01315.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T07:07:53Z","timestamp":1736924873000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2007.01315.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,27]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1111\/j.1445-5994.2007.01315.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2007.01315.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,27]]},"assertion":[{"value":"2007-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}